The US drug regulator approved a second vaccine against respiratory syncytial virus (RSV), its American developer Pfizer said Wednesday, a month after the authorization of the first shot against the pathogen, a leading cause ...
Jun 1, 2023
0
2
Respiratory syncytial virus (RSV) is a highly contagious and seasonal respiratory virus that mainly causes common cold symptoms in healthy adults but can cause more serious lung infections in infants, the immunocompromised ...
May 24, 2023
0
29
The first RSV vaccine designed to protect infants is under consideration by a panel of advisers to the U.S. Food and Drug Administration.
May 18, 2023
0
2
There is a current surge in respiratory syncytial virus (RSV) infections, especially among older children, according to a research letter published online May 15 in JAMA Pediatrics.
May 17, 2023
0
12
French pharmaceutical giant Sanofi announced trial results on Friday that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalized by more than 80 percent.
May 12, 2023
0
5
Experts have called for further scrutiny of a new Pfizer vaccine given during pregnancy to prevent respiratory infection in infants, after trials of a similar GSK vaccine were stopped after a rise in preterm birth and infant ...
May 10, 2023
0
54
The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.
May 10, 2023
0
3
For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. The hunt is over.
May 6, 2023
0
26
The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
May 3, 2023
0
10
The European Union's drug watchdog has recommended approval of pharmaceutical giant GSK's vaccine against the RSV respiratory virus for over-60s, the British firm said on Thursday.
Apr 27, 2023
0
1
